Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
企業コードSGHT
会社名Sight Sciences Inc
上場日Jul 15, 2021
最高経営責任者「CEO」Badawi (Paul)
従業員数216
証券種類Ordinary Share
決算期末Jul 15
本社所在地4040 Campbell Ave,
都市MENLO PARK
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号94025
電話番号14158890550
ウェブサイトhttps://www.sightsciences.com/
企業コードSGHT
上場日Jul 15, 2021
最高経営責任者「CEO」Badawi (Paul)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし